ライフサイエンスコーパス: liposome

1 t cell-bound IgE) and CD33L were on the same liposome.

2 hed to a biomolecule and many quenchers in a liposome.

3 imple co-administration of GBS67, CpGODN and liposomes.

4 ed on its conjugation to serve as anchor for liposomes.

5 muM for PC/PG 1:1 and 0.6 muM for PC/PG 7:3 liposomes.

6 ng liposomes compared with the non-targeting liposomes.

7 ntly expressed, purified and integrated into liposomes.

8 ies, and used to prepare placental-targeting liposomes.

9 was even observed in reconstituted cell-free liposomes.

10 00-fold higher than that of immunoglobulin G/liposomes.

11 duced by subsequently administered PEGylated liposomes.

12 citriol (1alpha,25-dihydroxyvitamin D3) into liposomes.

13 f a flotillin increases membrane fluidity of liposomes.

14 galin receptor in the internalization of the liposomes.

15 gainst doxorubicin liposomes and gemcitabine liposomes.

16 rocytes, and more selectively than PEGylated liposomes.

17 to PI5P-deprived liposomes or PI-containing liposomes.

18 with BH3 mimetics or clodronate-encapsulated liposomes.

19 ter depletion of macrophages with clodronate liposomes.

20 ant formed large oligomers when activated in liposomes.

21 ed by intrapulmonary pretreatment with SOCS3 liposomes.

22 atients and efficiently captured ganglioside-liposomes.

23 interventions with different tolerogenic PEG-liposomes.

24 The PEVs were smaller than liposomes (~150 vs 370 nm) and more stable, according to

25 Liposomes (~200 nm diameter) loaded with Fe(CN)(6)(4-) a

26 min along with TLR9 and STING ligands within liposomes, a well-established drug delivery system that

27 regulatory T cells in prediabetic mice, and liposome administration at the onset of hyperglycemia si

28 Liposome administration s.c., but not i.v., induced ChgA

29 After BDC2.5(mim)/calcitriol liposome administration, adoptive transfer of CD4(+) T c

30 After liposome administration, we followed the endogenous ChgA

31 ccine formulations, immunization using CoPoP liposomes admixed with recombinant RBD induces multiple

32 iated with cell proliferation as compared to liposomes alone.

33 (D)CDX-modified liposomes also participated in the endosome/lysosome pat

34 Optimized 200 nm liposomes anchored to a dsDNA chain led to an improvemen

35 ssipation capacity by which several sizes of liposome and DNA structures were compared with respect t

36 y the in vivo biodistribution profile of the liposome and GT3 individually.

37 were used to visualize the fine structure of liposomes and bilayer fragments by CryoTEM.

38 understand the reactions that occur between liposomes and detect heterogenous behavior in these reac

39 or in vitro binding to phosphoinositides and liposomes and for plant cell membrane association.

40 phosphatidylcholine/phosphatidylethanolamine liposomes and found that the presence of ApoE on liposom

41 vival study and compared against doxorubicin liposomes and gemcitabine liposomes.

42 delivery to the brain when incorporated into liposomes and has shown promise as a nanocarrier for tre

43 Staining of polyethylene-glycol-labeled liposomes and high performance liquid chromatography ana

44 on by depleting these cells using clodronate liposomes and inhibiting the inflammasome with a specifi

45 ique opens a new door for preparation of the liposomes and lipid-based nanoparticles by on-chip techn

46 SNAREs, using syntaxin-1-SNAP-25-containing liposomes and liposomes containing synaptobrevin (T and

47 otocol for scrambling the lipid asymmetry of liposomes and maybe cells without compromising their ove

48 The extract was incorporated in liposomes and penetration enhancer-containing vesicles (

49 Liposomes and proteoliposomes prepared with E. coli lipi

50 Furthermore, the triggered release of loaded liposomes and reuptake by target macrophages is studied.

51 on maintaining the physical integrity of the liposomes and the stability of the encapsulated drug.

52 nd physicochemical composition of individual liposomes and will facilitate the design and development

53 the J-form interacts with negatively charged liposomes and with MBB2, a monoclonal anti-DI antibody t

54 wo- and three-component synthetic membranes (liposomes) and the plasma membrane of human erythrocytes

55 ward lung in comparison to the CBSA/siS100A4@Liposome, and exhibited outstanding gene-silencing effec

56 encapsulation/adsorption of CpGODN into/onto liposomes, and have resulted in enhanced immunopotency c

57 (+)/H(+) antiporter was active in asymmetric liposomes, and it can be concluded that reconstitution a

58 membrane vesicles, small unilamellar vesicle liposomes, and rabbit erythrocytes.

59 more effective than free drugs, non-targeted liposomes, and single-agent controls and reduces severe

60 Liposomes, applied in the past as mass amplifiers and de

61 Incorporation of [Co(L1)](2+) into the liposome aqueous core, followed by dialysis against a so

62 Liposomes are potential nanocarrier-based biocompatible

63 The use of liposome as a vesicle can be a potential means to enhanc

64 laxis with free PEG or tolerogenic PEGylated liposomes as a strategy to reduce the amount of APA indu

65 e and demonstrates the utility of clodronate liposomes as an important tool in the study of invertebr

66 ively the outer leaflet of lipid bilayers of liposomes, as evidenced by leaflet-specific fluorescence

67 therapy has been successfully designed with liposome-based nanomedicine.

68 he amphiphilic [Co(L3)](2+) complex into the liposome bilayer produces a more highly shifted CEST pea

69 hosphatidylethanol was incorporated into the liposome bilayer to provide the nanovesicles with fluore

70 showed that in the inflamed brain anti-VCAM/liposomes bind to endothelium, not to leukocytes.

71 ty to bind physiological membranes in both a liposome-binding assay and MIN6 cells.

72 teristics (size and charge) compared to free liposomes but exhibited different structure and morpholo

73 showed strong affinities to PI5P-containing liposomes but not to PI5P-deprived liposomes or PI-conta

74 pplementation decreased membrane fluidity in liposomes, but did not affect ProP activity in proteolip

75 1,2-dimyristoyl-sn-glycero-3-phosphocholine) liposomes by single collisions at 10 mum diameter carbon

76 oading and release of radiotherapeutics from liposomes can be challenging in the clinical setting.

77 d liposomes, suggesting that (D)CDX-modified liposomes can potentially serve as a powerful therapeuti

78 We conclude that the cRGDyK-guided liposomes can specifically target the activated HSCs, bu

79 7 in conjunction with adsorption on cationic liposomes, can promote co-delivery leading to the induct

80 chemical composition of individual nanosized liposome cannot be resolved.

81 We show that, pH-sensitive liposomes co-encapsulating CpG ODN and cGAMP induced syn

82 Here, a liposome-coated mesoporous silica nanoparticle (lipoMSN)

83 e RNA ribonucleoprotein complex (RNP), while liposome-coating offers improved serum stability and enh

84 ectrochemical detection of single redox DMPC liposome collisions at polarized UMEs was investigated u

85 nt spikes corresponding to single redox DMPC liposome collisions with K(3)Fe(CN)(6)/K(4)Fe(CN)(6) as

86 promising efficacy was observed when 17-AAG liposomes combined with checkpoint blockade immunotherap

87 uorescence probe encapsulated in GM-modified liposomes compared to the uptake without free inhibitor

88 ions show a 3-fold increase of the targeting liposomes compared with the non-targeting liposomes.

89 non-viral vectors makes use of DNA/cationic liposome complexes (lipoplexes) to deliver the genetic m

90 ate readily electrostatically bound cationic liposomes composed of 1, 2-distearoyl-sn-glycero-3-phosp

91 Liposomes composed of RP+ST(LC)(()(low concentration)())

92 Analyzing a series of single-component liposomes composed of synthetic lipids of varying chain

93 of salivary gland macrophages by clodronate liposomes compromised the restoration of irradiation-imp

94 lved AFM-IR spectra acquired from individual liposomes confirmed the presence of peaks related to N-H

95 This technology is extended to microbubble-liposome conjugates, which exhibit a stronger response t

96 the biodistribution did not resemble that of liposome constructs currently used in the clinic.

97 fectiveness of AFM-IR in differentiating the liposome containing ciprofloxacin in dissolved or nanocr

98 s acyl chain specificity is only observed in liposomes containing 1,2-dioleoyl PA in the presence of

99 The targeting liposomes containing 10 mol% GM-modified lipids increase

100 Targeting liposomes containing 5 mol% GM-modified lipids enhanced

101 vesicles in the sample to be quantified and liposomes containing a pair of FRET fluorophores.

102 ionic exenatide adsorbs electrostatically to liposomes containing anionic diacyl phosphatidylglycerol

103 Liposomes containing both PE and PS bound to GAS6 and we

104 was inhibited with greater efficiency by the liposomes containing both PS and PE compared to a mixtur

105 cifically, the authors show that delivery of liposomes containing both the specific antigen recognize

106 Here we show that liposomes containing calcium, adenosine triphosphate, or

107 RBD into particulate form via admixing with liposomes containing cobalt-porphyrin-phospholipid (CoPo

108 t, it inhibits binding of the DEP1 domain to liposomes containing phosphatidic acid.

109 n and phosphatidylserine, and interacts with liposomes containing such lipids.

110 syntaxin-1-SNAP-25-containing liposomes and liposomes containing synaptobrevin (T and V liposomes, r

111 Furthermore, the liposome-containing peritoneal fluid contained significa

112 tidic acid headgroups (GMGTPA) occur without liposome content release, which contrasts with liposomes

113 resistive-pulses, suggesting that leakage of liposome contents occurs during translocation.

114 Thus, SPC-CHO liposome could be used as a promising carrier of HC.

115 we showed that the OrX subunit on its own in liposomes could detect volatile organic compounds (VOCs)

116 Taken together, 17-AAG liposomes could remodel the immunosuppressive microenvir

117 It was demonstrated that the OrX/Orco liposomes could sensitively and selectively detect their

118 mined the mechanisms whereby (D)CDX-modified liposomes cross the BBB in vivo using the brain efflux-i

119 Despite the fact that low dose 17-AAG liposomes demonstrated a limited therapeutic effect alon

120 d glycomimetic Langerin ligand conjugated to liposomes demonstrated specific and fast internalization

121 reover, reconstitution of 10xHis-OsPIP1;3 in liposomes demonstrated water channel activity, as reveal

122 a high throughput sensing device for single liposome detection.

123 Further investigation suggested that liposome disruption occurs at the nanopore orifice and i

124 stigation of the geometrical features of the liposome/DNA complex was carried out.

125 drug loaded MBs (DLMBs), in which DOX-loaded liposomes (DOX-LS) were conjugated to MBs, reduced spher

126 ministered in complex with folate-containing liposomes dramatically inhibit primary tumor growth via

127 Effectiveness of liposomes elaborated with rapeseed phospholipid (RP) ext

128 Our results shows that liposomes elaborated with RP, properly combined with oth

129 critical surface density of PAP(248-286) on liposomes enables peptide-mediated particle bridging int

130 Liposome-encapsulated clodronate was used to assess macr

131 hesized pulmonary surfactant (PS)-biomimetic liposomes encapsulating 2',3'-cyclic guanosine monophosp

132 ssess the chemical composition of individual liposomes encapsulating ciprofloxacin in dissolved and n

133 Use of liposomes encapsulating drug nanocrystals for the treatm

134 Synthetic liposomes encapsulating SOCS3 can rescue this defect and

135 Thus, liposomes encapsulating the single CD4(+) peptide, BDC2.

136 f these techniques such as spray drying, and liposome entrapment can degrade the bioactive compounds

137 articles and nanostructured lipid carriers), liposome entrapment, nanoprecipitation, freeze drying, s

138 from PR reconstituted in oppositely charged liposome environments disappeared when the NaCl concentr

139 This hybrid system (neutrophils loaded with liposomes ex vivo) efficiently migrates in vitro followi

140 Furthermore, uptake of anti-VCAM/liposomes exceeded that of anti-TfR and anti-ICAM counte

141 GEM/DOX liposomes exhibited a high HC in vitro and an increase i

142 Ephrin A2-targeted taxane liposomes exhibited sub-nanomolar (0.69 nM) apparent equ

143 ut any encapsulants, which not only made the liposome fabrication much easier without the need for pu

144 of markedly reducing the APA response to PEG-liposomes for ~2 months; the effectiveness was comparabl

145 as the key intermediate in the mechanism of liposome formation by microfluidic mixing in the channel

146 e of this work was to evaluate the effect of liposome formulation of paclitaxel (L-PTX) on neurotoxic

147 l the tumor microenvironment, we developed a liposome formulation to deliver a potential immunogenic

148 Liposome formulations are currently used in the clinic t

149 significantly higher ammonia levels than the liposome-free control, demonstrating efficient ammonia s

150 the requirement of Munc13 but not Munc18 for liposome fusion.

151 Calcium release from liposome-HGN can be spatially patterned to crosslink alg

152 Liposome-HGN provide stable, biocompatible isolation of

153 leased at essentially the same rate from the liposome-HGN.

154 ng of acyl chain-labeled fluorescent PIP2 in liposomes, implying clustering.

155 In vitro Rgd3 associates with liposomes in a PIP(2)-enhanced manner.

156 d effectively restore the circulation of PEG liposomes in animals with high pre-existing titers of AP

157 lert for the utilization of peptide modified liposomes in drug delivery, especially when carrying low

158 y charged compared to net negatively charged liposomes in low-salt buffer solutions, a drop of the ap

159 rated that BON1 could mediate aggregation of liposomes in response to Ca(2+) .

160 plications and have benefits over comparable liposomes in terms of greater stability, lower cost and

161 show that the method is suitable to measure liposomes in the presence of serum proteins and can yiel

162 Synthetic D-octadecapeptide tubulates liposomes in vitro and the ER in cells.

163 romote the transportation of (D)CDX-modified liposomes in vivo or in vitro, as assessed with alpha7-k

164 somes and found that the presence of ApoE on liposomes increased deposition of C1q and C4b from serum

165 Amikacin liposome inhalation suspension is recommended for treatm

166 Both AM-derived EVs and synthetic SOCS3 liposomes inhibited the activation of STAT3 and STAT6 as

167 In contrast, T182I was inefficient in both liposome insertion and permeabilization.

168 hic lipid packing sensor motif, confirmed by liposome interaction studies.

169 toskeleton capable of transforming spherical liposomes into elongated shapes, such as rod-like compar

170 Cavitation of MBs co-injected with liposomes into tumours expressing high levels of EGFR re

171 GL-1)-targeted BTZ and ROCK inhibitor-loaded liposomes is more effective than free drugs, non-targete

172 lation into cell-sized compartments, such as liposomes, is one of the major bottom-up approaches to b

173 demonstrate that the Syt-7 C2AB tandem binds liposomes lacking phosphatidylinositol-4,5-bisphosphate

174 ver macrophages by treatment with clodronate liposomes largely abolished the beneficial metabolic eff

175 In the present study, using liposome-leakage and cytotoxicity assays, LC-MS/MS-based

176 nformational changes in GP2 and permit virus-liposome lipid mixing.

177 e this mechanism with respect to the size of liposomes, lipid composition of the membrane, crowding a

178 stems gave high antigen loading (> 85%) with liposomes, lipid nanoparticles and emulsions being <200

179 Thermosensitive liposomes (LipoTherm) were prepared with gold nanocluste

180 ts of these techniques, the development of a liposome loaded radiopharmaceutical construct for enhanc

181 Biodistribution of liposome-loaded neutrophils in a human-disease-relevant

182 The migratory behavior of liposome-loaded neutrophils is confirmed in vivo by demo

183 Binding to lipids was observed in liposomes, low-density lipoproteins, cell membranes, and

184 (DOX)-loaded lysolipid temperature-sensitive liposomes (LTSLs) are a promising stimuli-responsive dru

185 protein-free lipid system based on cationic liposomes (LUVs, large unilamellar vesicles) and anionic

186 trate calcium-mediated fusion events between liposome made of glycerolmonoalkyl glycerol tetraether l

187 anoresponsive nanovesicles, which consist of liposomes made from the artificial phospholipid Rad-PC-R

188 posome content release, which contrasts with liposomes made of bilayer-forming EggPA lipids that disp

189 e questioned whether peptide modification on liposomes may induce serious toxicity associated with im

190 se results demonstrate that megalin-targeted liposomes may offer an opportunity to enhance the delive

191 ore highly stable complexes, delivered using liposomes, may provide improved opportunities for oxidov

192 tion temperature) is a key parameter for the liposome membrane electroporation process and hence for

193 heless, the G179P variant could permeabilize liposome membranes, suggesting that large BAX oligomers

194 Detergent-induced lipid scrambling of liposomes mimicking the charge asymmetry of bacterial me

195 rdered and disordered phases within a single liposome, namely differences in membrane thickness and m

196 this study was to develop megalin-targeting liposome nanocarriers for placental drug delivery.

197 with soluble mitogenic cues and coated with liposomes of defined compositions, to form supported lip

198 By using liposomes of different composition, or HGN of different

199 surements of single-virus fusion kinetics to liposomes of different sizes.

200 ontaining liposomes but not to PI5P-deprived liposomes or PI-containing liposomes.

201 lation compared to the non-targeting control liposomes (p < .0001), as measured by both tissue extrac

202 xperiment, likely because of an inability of liposome particles containing the cytotoxic drug to cros

203 ted by SPR measurements that showed stronger liposome partitioning of RBD-CRD relative to CRD alone.

204 mutations of these RBD residues reduced the liposome partitioning of RBD-CRD.

205 e prepared four cationic systems (emulsions, liposomes, polymeric nanoparticles and solid lipid nanop

206 various content of cholesterol were used for liposome preparation and it was demonstrated, that an in

207 parameter affecting the final size of formed liposomes prepared by microfluidic mixing of an ethanol

208 rent levels (0.25%-2%, w/v) were loaded into liposomes prepared from soy phosphatidylcholine (SPC) wi

209 Flow-cytometry of allografts revealed liposome presence in CD45 cells, and reduced numbers of

210 The liposome-protein corona is a dynamic interface that regu

211 The novel cationic liposomes-protein conjugate complex (GBS67-CpGODN+L) sha

212 fluorescent probes between the two types of liposomes provides a useful approach to better understan

213 king onto the same ECF module, but a minimal liposome-reconstituted system, required to substantiate

214 inducing vapor nanobubbles that rupture the liposome, releasing cargo within milliseconds.

215 17-AAG delivered by liposome remodeled the immunosuppressive microenvironmen

216 ts of the drug pairs and compare them to DOX liposomes representative of DOXIL(R).

217 (TAP) by single-turnover analyses at single-liposome resolution.

218 liposomes containing synaptobrevin (T and V liposomes, respectively), and fluorescent probes to moni

219 QS-21 inclusion in the liposomes results in an enhanced antigen-specific polyfu

220 Cosedimentation experiments with liposomes revealed that the Aster-B GRAM domain binds to

221 e, we present an iron-crosslinked rosmarinic liposome (Rososome) which can load high contents of drug

222 lex, a virus-like particle, a polymer, and a liposome sample, when compared to a (210)Po based bipola

223 Depending on the concentration of liposomes, secondary binding may also lead to liposomal

224 resent study, using fluorescence microscopy, liposome sedimentation, differential scanning calorimetr

225 ning both PS and PE compared to a mixture of liposomes separately composed of PS and PE.

226 The DOPr agonist DADLE was coupled to a liposome shell for targeting DOPr-positive nociceptors a

227 ng protein incorporated in large unilamellar liposomes showing a stable lipid asymmetry.

228 ncrease in fluidity results in a decrease of liposome size as analyzed by DLS.

229 -based nanocarriers, including nanoemulsion, liposomes, SLN, NLC etc.

230 metallic/inorganic NPs, and lipid-based NPs (Liposome, solid-lipid nanoparticles (SLNs), and nanostru

231 Ganglioside-liposomes specifically bound to CD169 and were internali

232 reduction analysis revealed that ganglioside-liposomes specifically targeted CD14(+) CD169(+) monocyt

233 rotocadherin gammaB6 ectodomains tethered to liposomes spontaneously assemble into linear arrays at m

234 in SPC-CHO-0.5%HC (P < 0.05) (85.42%), while liposome stabilized with GLY had the highest EE (74.54%)

235 lying crossing of the BBB by (D)CDX-modified liposomes, suggesting that (D)CDX-modified liposomes can

236 Liposome-supported peritoneal dialysis (LSPD) with trans

237 rmationally intact display of the RBD on the liposome surface.

238 Results of liposome-swelling assays suggested that VcChiP can trans

239 ferences in the response of the two types of liposome systems to DMSO in terms of the bilayer thermot

240 mography imaging affirmed specific anti-VCAM/liposome targeting to inflamed brain in mice.

241 Outer membrane vesicles (OMVs) are spherical liposomes that are secreted by almost all forms of Gram-

242 We first construct peptide-caged liposomes that treat protease activity as two-valued (i.

243 assembled into nanoparticles or entrapped in liposomes that were electrostatically coated with algina

244 he therapeutic efficiency of (D)CDX-modified liposomes that were formulated with doxorubicin against

245 Raman-scattered light from a single-trapped liposome, the effect of the protein on short-range order

246 In B. thailandensis liposomes, the bacteriohopanetetrol hopanoid, and potent

247 assembly of macromolecular structures inside liposomes, the cytoskeleton in particular, stands as a c

248 Compared to natural phospholipid liposomes, the photo-release was possible at 40 times lo

249 Compared to liposomes, the structure provides a significantly higher

250 h to gene therapy of NPC1 using Trojan horse liposomes (THLs), wherein the plasmid DNA is encapsulate

251 by demonstrating the delivery of drug-loaded liposomes to an inflamed skeletal muscle in mice.

252 y for the selection of nanoparticles such as liposomes to be used as acoustic probes for the detectio

253 ious cargos like nanoparticles, micelles and liposomes to deliver drugs and genes to the cancer cell.

254 The ability of the targeting liposomes to enhance accumulation of a fluorescence prob

255 have been used to release therapeutics from liposomes to enhance the distribution/delivery in a targ

256 We loaded doxorubicin and erlotinib into liposomes to enhance their translocation across the BBB

257 g megalin thus offers an opportunity for the liposomes to hitchhike into the SynT, thus enriching the

258 lity of injected neutrophils to carry loaded liposomes to inflammation sites.

259 ernalized redox molecules from translocating liposomes to the CFE surface.

260 x participated in delivering (D)CDX-modified liposomes to the plasma membrane (PM).

261 chanisms enabling (D)CDX (and its associated liposomes) to cross an in vitro BBB using a simulated ce

262 ribed the mechanisms whereby (D)CDX-modified liposomes traverse the blood-brain barrier (BBB).

263 median survival time, double that of the DOX liposome-treated group and 3.4-fold greater than that of

264 The GEM/DOX liposome-treated group had the longest median survival t

265 After BDC2.5(mim)/calcitriol liposome treatment and expansion of ChgA-specific periph

266 formulation with R848 using thermosensitive liposomes (TSLs) as a delivery vehicle.

267 93 cells and tested for binding to lipids in liposomes using density centrifugation.

268 When incorporated into liposomes using in vitro protein synthesis, the transmem

269 Methods: GT3 was loaded into liposomes using passive loading.

270 yo-EM structural analysis of MPs embedded in liposomes, using the well-characterized AcrB as a protot

271 he formulation containing citric acid-loaded liposomes was administered intraperitoneally at two diff

272 orescent probe encapsulated within targeting liposomes was also probed in an in vitro model of the hu

273 toferrin (LF) was studied; lipid membrane of liposomes was characterized (bilayer size, chain conform

274 Transport of (D)CDX and its modified liposomes was dominantly mediated via the lipid raft/cav

275 onal (3D) reconstruction of AcrB embedded in liposomes was obtained at 3.9 angstrom resolution.

276 The 17-AAG liposomes was prepared by thin film dispersion methods.

277 alysis (LSPD) with transmembrane pH-gradient liposomes was previously shown to enhance ammonia remova

278 on bovine serum albumin-water (D(BSA/w)) and liposome-water distribution ratios (D(lip/w)) of the che

279 the fluorescent probes placed on the T and V liposomes, we observed a striking asymmetry in both lipi

280 These OrX/Orco liposomes were covalently attached to a gold surface mod

281 mic Force Microscopy (AFM) revealed that the liposomes were covalently attached to the surface withou

282 Liposomes were efficiently radiolabelled (57%) within 1

283 Hence, GEM/DOX liposomes were further investigated in a long-term survi

284 Stability and size of the liposomes were more affected by gastric digestion than i

285 The tPA-loaded liposomes were PEGylated to improve their stability, and

286 ptide used as a drug to treat diabetes, with liposomes were studied by isothermal titration calorimet

287 myristoyl-sn-glycero-3-phosphocholine (DMPC) liposomes were the model system chosen to mimic the prot

288 xes can be stably incorporated into cationic liposomes where it retains very good bioavailability, ap

289 smid DNA is encapsulated in 100 nm pegylated liposomes, which are targeted to organs with a monoclona

290 apsulated in non-immunogenic glioma-targeted liposomes, which may contribute to the development of be

291 ed by more than 200-fold upon replacement of liposomes with bacteriophage Qbeta virus-like particles

292 Cryo-electron tomography of liposomes with bound MACA showed an amorphous protein la

293 D97 was compared between PR reconstituted in liposomes with different net headgroup charges and equil

294 Liposomes with Gd-complexes (Gd-lip) co-encapsulated wit

295 ill facilitate the design and development of liposomes with greater therapeutic benefits.

296 e membrane curvature-it was less affected in liposomes with high curvature.

297 By combining acoustic-cavitation-sensitive liposomes with radiopharmaceuticals this research repres

298 uces a novel strategy for the development of liposomes with robust stability, high drug loading and s

299 interface that regulates the interaction of liposomes with the physiological environment.

300 Activatable liposomes, with drug release resulting from local heatin